FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine; it can be used for the treatment of hemoblastosis. A method for the treatment of hemoblastosis in an individual includes the administration of effective amount of a liposomal composition containing cytarabine and daunorubicin incapsulated together in a molar ratio of 5:1 (CPX-351), and FLT-3 inhibitor selected from a group consisting of from quizartinib, midostaurin, tandutinib, sorafenib, sunitinib, lestaurtinib, crenolanib, gilteritinib, AST-487, dovitinib and linifanib. In this case, the specified liposomal composition and FLT-3 are administered simultaneously, or the specified liposomal composition is administered before the treatment with FLT-3 inhibitor.
EFFECT: invention provides for an increase in the efficiency of treatment of hemoblastosis due to a synergetic effect of a combination of CPX-351 and FLT-3 inhibitor.
4 cl, 11 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PERSONALIZED MEDICAL TESTING EX VIVO FOR HEMATOLOGICAL NEOPLASMS | 2010 |
|
RU2636614C2 |
| COMBINATION OF MCL-1 INHIBITOR AND MIDOSTAURIN, ITS APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2019 |
|
RU2818453C2 |
| HDM2-P53 INHIBITOR AND BCL2 INHIBITOR INTERACTION COMBINATIONS AND THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2793123C2 |
| COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
| METHOD OF ASSESSING MINIMAL RESIDUAL DISEASE (MRD) BY MULTICOLOR FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN THE POST-INDUCTION PHASE OF TREATMENT | 2022 |
|
RU2802131C1 |
| PREDICTION OF RESPONSE TO ALVICIDIB BY ANALYSIS OF MITOCHONDRION PROFILE | 2016 |
|
RU2717829C2 |
| PHARMACEUTICALLY ACTIVE COMPOUNDS | 2013 |
|
RU2654942C2 |
| ANTI-CANCER THERAPY, DIRECTED AGAINST CANCER STEM CELLS AND FORMS OF CANCER, RESISTANT TO TREATMENT BY MEDICATIONS | 2010 |
|
RU2568834C2 |
| COMBINATION OF LSD1 INHIBITORS FOR TREATING HAEMATOLOGICAL MALIGNANT DISEASES | 2017 |
|
RU2816659C2 |
| COMBINATIONS OF LSD1 INHIBITORS FOR TREATING HAEMATOLOGICAL MALIGNANT DISEASES | 2017 |
|
RU2766259C2 |
